東方電熱(300217.SZ):目前公司"年產2萬噸鋰電池預鍍鎳鋼基帶項目"沒有達到滿產
格隆匯6月20日丨有投資者問,公司在2022年和無錫金楊和東山精密分別簽了8萬噸和5萬噸的預鍍鎳協議,期限基本都在6年到6年半,目前進度如何,按照公司目前年2萬噸的生產能力,是不是應該已經滿產了?一旦有新的訂單落地,公司是不是會產能不夠呢?
東方電熱(300217.SZ)在互動平台表示,公司2022年與無錫金楊和東山精密分別簽了8萬噸和5萬噸的預鍍鎳協議,目前上述協議正在履行中;未來,公司有望向無錫金楊、東山精密逐步放量供貨。此外,目前為止,公司"年產2萬噸鋰電池預鍍鎳鋼基帶項目"沒有達到滿產;公司未來將根據預鍍鎳材料市場需求情況適時啟動預鍍鎳擴產計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.